The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes

Dados Bibliográficos

ID9103028
AutoresYixue Shao (0000-0003-1410-5455, Tulane University, autor correspondente), Charles Stoecker (0000-0001-5438-9312, Tulane University, autor correspondente), Dongzhe Hong (0000-0002-6400-9667, Tulane University, autor correspondente), Elizabeth Nauman (0009-0008-8092-7071, Louisiana Public Health Institute), Vivian Fonseca (0000-0002-3381-7151, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans), Gang Hu (0000-0002-7892-5578, Pennington Biomedical Research Center, Baton Rouge), Alessandra N Bazzano (0000-0002-8299-2626, Tulane University), Daniel Fort (0000-0002-3759-4063, Ochsner Health, New Orleans, LA), Edmond K Kabagambe (0000-0002-8993-3186, Ochsner Health, New Orleans, LA), Lizheng Shi (0000-0002-7827-6766, Tulane University, autor correspondente)
Ano2023
Volume61
Fascículo3
Páginas157-164
Data de publicação2023-03-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoMedical Care (JOURNAL)
Identificadores do periódicoISSN: 0025-7079 • E-ISSN: 1537-1948
EditoraOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0000000000001816
PMID36728398
OpenAlexW4318917671
IdiomaEN
Referências citadas18

AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health records stored in REACHnet. The study period was from 2013 to February 2020. The comprehensive metabolic risk factors included the primary outcome of glycated hemoglobin (HbA1c) (as the primary outcome) and the secondary outcomes of body mass index (BMI), systolic blood pressure (BP), and low-density lipoprotein cholesterol. RESULTS: Receiving any NFFCCM was associated with improvement in all outcomes measures: a reduction in HbA1c of 0.063% (95% CI: 0.031%-0.094%; P <0.001), a reduction in BMI of 0.155 kg/m 2 (95% CI: 0.029-0.282 kg/m 2 ; P =0.016), a reduction in systolic BP of 0.816 mm Hg (95% CI: 0.469-1.163 mm Hg; P <0.001), and a reduction in low-density lipoprotein cholesterol of 1.779 mg/dL (95% CI: 0.988 2.570 mg/dL; P <0.001). Compared with the control group, the treatment group had 1.6% more patients with HbA1c <7% (95% CI: 0.3%-2.9%; P =0.013). CONCLUSIONS: Patients with diabetes in Louisiana receiving NFFCCM experienced better control of HbA1c, BMI, BP, and low-density lipoprotein outcomes

Blood pressure · Body mass index · Diabetes mellitus · Glycated hemoglobin · Health care · Reimbursement · Type 2 diabetes · Chronic Disease Management Strategies · Diabetes Management and Education · Diabetes Treatment and Management · Endocrinology · Internal Medicine · Medicine